Global Nuclear Medicine Market By Type (Diagnosis (Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT)) Treatment, Radioactive Iodine Therapy, Brachytherapy, Chemotherapy, Hormone Therapy, Proton Therapy, Alpha Emitters, Stereotactic Body Radiotherapy, Others) By Application (Thyroid disease, Gall bladder disease, Heart conditions, Cancer, Alzheimer’s disease, Endocrine Tumors, Neurology Disorders, Lymphoma, Others) By End Users (Hospitals and Clinics, Diagnostic Centers, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Evolution of revolutionary technologies for diagnostic testing to innovative products introduced to treat identified diseases, medical discipline has shown tremendous progress in the past decades. Nuclear medicine imaging is a non-invasive procedure used to diagnose and treat various disorders and is one of the safest imaging modalities in diagnostic testing today. Advancements in diagnostic imaging is bringing in more use of nuclear medicine. In the last few years, there have been remarkable innovation in nuclear imaging technologies to enhance image quality and reduce emission-transmission mistach artifacts. In particular, the use of computed tomography (CT) has been growing progressively worldwide. Nuclear imaging is being utilised more frequently as a result of the discovery of novel radiopharmaceuticals in new clinical areas such as orthopaedics and neurology, as opposed to historically used clinical areas such as oncology and cardiology. However, nuclear imaging industry is poised to face challenges like decreased federal support, heavy regulatory requirements, inadequate supply of radionuclides for research, etc. On the other hand the development of new radioisotopes tracers will take nuclear medicine market ahead and enable greater specificity to target individual tumours or diseases.
In terms of revenue, global nuclear medicine market was valued at US$ 8.1 Bn in 2021 growing at a CAGR of 13.2% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Nuclear Medicine Market Revenue & Forecast, (US$ Million), 2015 – 2030
Type Outlook
Based on the type segment, the global nuclear medicine market is segmented into diagnosis and treatment. Diagnosis segment is further classified into Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT), and this segment holds the highest share in the market in the year 2021. Moreover the treatment segment which is classified into brachytherapy, chemotherapy, hormone therapy, proton therapy and others is estimated to be the fastest growing segment in the forecast period. The clinical utility of SPECT and PET, as well as general nuclear medicine, continues to be a viable mainstay in assisting physicians and healthcare facilities with patient care. Nuclear medicine systems' technological advancements have remained essentially constant. PET/MR is being studied for clinical value; however it is a costly method. The use of SPECT/PET for therapeutic purposes, as well as its replacement in the installed base, is a significant recent development. Another SPECT/CT advancement is quantification and its application in oncology, as well as the expanding use of radionuclide therapy. Furthermore, SPECT/PET advancement is the development of solid-state technologies, however these are currently mostly for research purposes and somewhat narrow applications, such as organ imaging and specialised tracers. On the PET side, novel acquisition approaches include continuous bed motion, which enables tailored acquisition and routine inclusion of respiratory motion correction. Another PET innovation is the growing use of large-bore PET scans for radiation therapy planning, which is becoming a more common application for PET.
Application Outlook
Based on the application, the global nuclear medicine market is segmented into thyroid disease, gall bladder disease, heart conditions, cancer, Alzheimer’s disease and others. In both developed and developing countries, cardiovascular disease has been the main cause of death. Nuclear cardiology is a subspecialty of nuclear medicine that focuses on cardiovascular illnesses. Because cardiovascular disease remains one of the most serious dangers to human health and longevity in many nations, nuclear cardiology can help patients with cardiovascular illness in a variety of ways. The recent advancement of computed tomography (CT)/magnetic resonance imaging (MRI) technology, as well as increased concerns about patient radiation exposure, continue to pose significant hurdles for nuclear cardiology. In response to these problems, great discoveries and developments in the field of myocardial perfusion imaging using nuclear medicine are currently underway. As a result, improvements in nuclear medicine will build a major road for treating many ailments in the coming years.
Region Outlook
Based on region, North America had the highest share in the nuclear medicine market in the year in the year 2021. Nuclear medicine has grown in popularity in the United States as a result of technological advances such as hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis and therapy, and the development of molecular imaging based on the tracer principle, which is not based on radioisotopes. For the field to continue to flourish, cost-effectiveness statistics and evidence that nuclear medicine operations improve patient outcomes will be required. Nuclear medicine physicians and radiologists will need greater anatomic and molecular imaging training. To ensure that future physicians are sufficiently educated, new educational models are being developed.
Competitive Landscape
The report provides both, qualitative and quantitative research of global nuclear medicine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key players operating in the global nuclear medicine market are listed below:
- Advanced Accelerator Applications
- Alliance Medical GmbH
- J. Madan & Co.
- Bracco Diagnostic Inc.
- BWX Technologies. Inc.
- Cardinal Health.
- Curium
- EDH Nuclear Medicine & Healthcare Services Ltd. Co.
- General Electric Company
- IBA Radiopharma Solutions
- Jubilant Pharma Limited
- Lantheus
- Other Market Participants
Global Nuclear Medicine Market
By Type
- Diagnosis
- Positron Emission Tomography (PET)
- Single-Photon Emission Computed Tomography (SPECT).
- Treatment
- Radioactive iodine therapy
- Brachytherapy
- Chemotherapy
- Hormone Therapy
- Proton Therapy
- Alpha emitters
- Stereotactic body radiotherapy
- Others
By Application
- Thyroid disease
- Gall bladder disease
- Heart conditions
- Alzheimer’s disease
- Endocrine Tumors
- Neurology Disorders
- Lymphoma
- Other
By End Users
- Hospitals and Clinics
- Diagnostic Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 - 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Nuclear Medicine Market
6. Market Synopsis:
Nuclear Medicine Market
7. Nuclear Medicine Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Nuclear Medicine Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Nuclear Medicine Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Nuclear Medicine Market
8. Global Nuclear Medicine Market Analysis and Forecasts, 2022 -
2030
8.1. Overview
8.1.1. Global
Nuclear Medicine Market Revenue (US$ Mn)
8.2. Global
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Diagnosis
(Definition, Market Estimation and Penetration, 2015 - 2021, Market Estimation
(2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Positron Emission Tomography
(PET) , Single-Photon Emission Computed Tomography (SPECT).)
8.2.1.1. Positron Emission Tomography (PET)
8.2.1.2. Single-Photon Emission Computed Tomography (SPECT).
8.2.2. Treatment
(Definition, Market Estimation and Penetration, 2015 - 2021, Market Estimation
(2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Radioactive iodine therapy ,
Brachytherapy, Chemotherapy, Hormone Therapy, Proton Therapy, Alpha emitters ,
Stereotactic body radiotherapy, Others )
8.2.2.1. Radioactive iodine therapy
8.2.2.2. Brachytherapy
8.2.2.3. Chemotherapy
8.2.2.4. Hormone Therapy
8.2.2.5. Proton Therapy
8.2.2.6. Alpha emitters
8.2.2.7. Stereotactic body radiotherapy
8.2.2.8. Others
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Nuclear Medicine Market Analysis and Forecasts, 2022 -
2030
9.1. Overview
9.2. Global
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Thyroid
disease
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Gall
bladder disease
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.2.3. Heart
conditions
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 - 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 - 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 - 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 - 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 - 2030
9.2.4. Cancer
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 - 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 - 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 - 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 - 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 - 2030
9.2.5. Alzheimer’s
disease
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 - 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 - 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 - 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 - 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 - 2030
9.2.6. Endocrine
Tumors
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2021
9.2.6.3. Market Forecast, 2022 - 2030
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2021
9.2.6.5.1.2. Market
Forecast, 2022 - 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2021
9.2.6.5.2.2. Market
Forecast, 2022 - 2030
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2021
9.2.6.5.3.2. Market
Forecast, 2022 - 2030
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2021
9.2.6.5.4.2. Market
Forecast, 2022 - 2030
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2021
9.2.6.5.5.2. Market
Forecast, 2022 - 2030
9.2.7. Neurology
Disorders
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2021
9.2.7.3. Market Forecast, 2022 - 2030
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market
Estimation, 2015 - 2021
9.2.7.5.1.2. Market
Forecast, 2022 - 2030
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2021
9.2.7.5.2.2. Market
Forecast, 2022 - 2030
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2021
9.2.7.5.3.2. Market
Forecast, 2022 - 2030
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2021
9.2.7.5.4.2. Market
Forecast, 2022 - 2030
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market
Estimation, 2015 - 2021
9.2.7.5.5.2. Market
Forecast, 2022 - 2030
9.2.8. Lymphoma
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2021
9.2.8.3. Market Forecast, 2022 - 2030
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1. Market
Estimation, 2015 - 2021
9.2.8.5.1.2. Market
Forecast, 2022 - 2030
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2015 - 2021
9.2.8.5.2.2. Market
Forecast, 2022 - 2030
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1. Market
Estimation, 2015 - 2021
9.2.8.5.3.2. Market
Forecast, 2022 - 2030
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1. Market
Estimation, 2015 - 2021
9.2.8.5.4.2. Market
Forecast, 2022 - 2030
9.2.8.5.5. Latin America
9.2.8.5.5.1. Market
Estimation, 2015 - 2021
9.2.8.5.5.2. Market
Forecast, 2022 - 2030
9.2.9. Other
9.2.9.1. Definition
9.2.9.2. Market Estimation and Penetration, 2015 - 2021
9.2.9.3. Market Forecast, 2022 - 2030
9.2.9.4. Compound Annual Growth Rate (CAGR)
9.2.9.5. Regional Bifurcation
9.2.9.5.1. North America
9.2.9.5.1.1. Market
Estimation, 2015 - 2021
9.2.9.5.1.2. Market
Forecast, 2022 - 2030
9.2.9.5.2. Europe
9.2.9.5.2.1. Market
Estimation, 2015 - 2021
9.2.9.5.2.2. Market
Forecast, 2022 - 2030
9.2.9.5.3. Asia Pacific
9.2.9.5.3.1. Market
Estimation, 2015 - 2021
9.2.9.5.3.2. Market
Forecast, 2022 - 2030
9.2.9.5.4. Middle East and Africa
9.2.9.5.4.1. Market
Estimation, 2015 - 2021
9.2.9.5.4.2. Market
Forecast, 2022 - 2030
9.2.9.5.5. Latin America
9.2.9.5.5.1. Market
Estimation, 2015 - 2021
9.2.9.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Nuclear Medicine Market Analysis and Forecasts, 2022 -
2030
10.1. Overview
10.2. Global
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By End Users
10.2.1. Hospitals
and Clinics
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Diagnostic
centers
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By End
Users
11. North America Nuclear Medicine Market Analysis and Forecasts,
2022 - 2030
11.1. Overview
11.1.1. North
America Nuclear Medicine Market Revenue (US$ Mn)
11.2. North
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Type
11.2.1. Diagnosis
11.2.1.1. Positron Emission Tomography (PET)
11.2.1.2. Single-Photon Emission Computed Tomography (SPECT).
11.2.2. Treatment
11.2.2.1. Radioactive iodine therapy
11.2.2.2. Brachytherapy
11.2.2.3. Chemotherapy
11.2.2.4. Hormone Therapy
11.2.2.5. Proton Therapy
11.2.2.6. Alpha emitters
11.2.2.7. Stereotactic body radiotherapy
11.2.2.8. Others
11.3. North
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1. Thyroid
disease
11.3.2. Gall
bladder disease
11.3.3. Heart
conditions
11.3.4. Cancer
11.3.5. Alzheimer’s
disease
11.3.6. Endocrine
Tumors
11.3.7. Neurology
Disorders
11.3.8. Lymphoma
11.3.9. Other
11.4. North
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By End Users
11.4.1. Hospitals
and Clinics
11.4.2. Diagnostic
centers
11.4.3. Others
11.5. North
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.1.1.1. Diagnosis
11.5.1.1.1.1. Positron
Emission Tomography (PET)
11.5.1.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
11.5.1.1.2. Treatment
11.5.1.1.2.1. Radioactive
iodine therapy
11.5.1.1.2.2. Brachytherapy
11.5.1.1.2.3. Chemotherapy
11.5.1.1.2.4. Hormone
Therapy
11.5.1.1.2.5. Proton
Therapy
11.5.1.1.2.6. Alpha
emitters
11.5.1.1.2.7. Stereotactic
body radiotherapy
11.5.1.1.2.8. Others
11.5.1.2. U.S Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.1.2.1. Thyroid disease
11.5.1.2.2. Gall bladder disease
11.5.1.2.3. Heart conditions
11.5.1.2.4. Cancer
11.5.1.2.5. Alzheimer’s disease
11.5.1.2.6. Endocrine Tumors
11.5.1.2.7. Neurology Disorders
11.5.1.2.8. Lymphoma
11.5.1.2.9. Other
11.5.1.3. U.S Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By
End Users
11.5.1.3.1. Hospitals and Clinics
11.5.1.3.2. Diagnostic centers
11.5.1.3.3. Others
11.5.2. Canada
11.5.2.1. Canada Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
11.5.2.1.1. Diagnosis
11.5.2.1.1.1. Positron
Emission Tomography (PET)
11.5.2.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
11.5.2.1.2. Treatment
11.5.2.1.2.1. Radioactive
iodine therapy
11.5.2.1.2.2. Brachytherapy
11.5.2.1.2.3. Chemotherapy
11.5.2.1.2.4. Hormone
Therapy
11.5.2.1.2.5. Proton
Therapy
11.5.2.1.2.6. Alpha
emitters
11.5.2.1.2.7. Stereotactic
body radiotherapy
11.5.2.1.2.8. Others
11.5.2.2. Canada Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
11.5.2.2.1. Thyroid disease
11.5.2.2.2. Gall bladder disease
11.5.2.2.3. Heart conditions
11.5.2.2.4. Cancer
11.5.2.2.5. Alzheimer’s disease
11.5.2.2.6. Endocrine Tumors
11.5.2.2.7. Neurology Disorders
11.5.2.2.8. Lymphoma
11.5.2.2.9. Other
11.5.2.3. Canada Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
11.5.2.3.1. Hospitals and Clinics
11.5.2.3.2. Diagnostic centers
11.5.2.3.3. Others
11.5.3. Mexico
11.5.3.1. Mexico Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
11.5.3.1.1. Diagnosis
11.5.3.1.1.1. Positron
Emission Tomography (PET)
11.5.3.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
11.5.3.1.2. Treatment
11.5.3.1.2.1. Radioactive
iodine therapy
11.5.3.1.2.2. Brachytherapy
11.5.3.1.2.3. Chemotherapy
11.5.3.1.2.4. Hormone
Therapy
11.5.3.1.2.5. Proton
Therapy
11.5.3.1.2.6. Alpha
emitters
11.5.3.1.2.7. Stereotactic
body radiotherapy
11.5.3.1.2.8. Others
11.5.3.2. Mexico Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
11.5.3.2.1. Thyroid disease
11.5.3.2.2. Gall bladder disease
11.5.3.2.3. Heart conditions
11.5.3.2.4. Cancer
11.5.3.2.5. Alzheimer’s disease
11.5.3.2.6. Endocrine Tumors
11.5.3.2.7. Neurology Disorders
11.5.3.2.8. Lymphoma
11.5.3.2.9. Other
11.5.3.3. Mexico Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
11.5.3.3.1. Hospitals and Clinics
11.5.3.3.2. Diagnostic centers
11.5.3.3.3. Others
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Type
11.5.4.1.1. Diagnosis
11.5.4.1.1.1. Positron
Emission Tomography (PET)
11.5.4.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
11.5.4.1.2. Treatment
11.5.4.1.2.1. Radioactive
iodine therapy
11.5.4.1.2.2. Brachytherapy
11.5.4.1.2.3. Chemotherapy
11.5.4.1.2.4. Hormone
Therapy
11.5.4.1.2.5. Proton
Therapy
11.5.4.1.2.6. Alpha
emitters
11.5.4.1.2.7. Stereotactic
body radiotherapy
11.5.4.1.2.8. Others
11.5.4.2. Rest of North America Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Application
11.5.4.2.1. Thyroid disease
11.5.4.2.2. Gall bladder disease
11.5.4.2.3. Heart conditions
11.5.4.2.4. Cancer
11.5.4.2.5. Alzheimer’s disease
11.5.4.2.6. Endocrine Tumors
11.5.4.2.7. Neurology Disorders
11.5.4.2.8. Lymphoma
11.5.4.2.9. Other
11.5.4.3. Rest of North America Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By End Users
11.5.4.3.1. Hospitals and Clinics
11.5.4.3.2. Diagnostic centers
11.5.4.3.3. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By Type
11.6.3. By
Application
11.6.4. By End
Users
12. Europe Nuclear Medicine Market Analysis and Forecasts, 2022 -
2030
12.1. Overview
12.1.1. Europe
Nuclear Medicine Market Revenue (US$ Mn)
12.2. Europe
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Diagnosis
12.2.1.1. Positron Emission Tomography (PET)
12.2.1.2. Single-Photon Emission Computed Tomography (SPECT).
12.2.2. Treatment
12.2.2.1. Radioactive iodine therapy
12.2.2.2. Brachytherapy
12.2.2.3. Chemotherapy
12.2.2.4. Hormone Therapy
12.2.2.5. Proton Therapy
12.2.2.6. Alpha emitters
12.2.2.7. Stereotactic body radiotherapy
12.2.2.8. Others
12.3. Europe
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. Thyroid
disease
12.3.2. Gall
bladder disease
12.3.3. Heart
conditions
12.3.4. Cancer
12.3.5. Alzheimer’s
disease
12.3.6. Endocrine
Tumors
12.3.7. Neurology
Disorders
12.3.8. Lymphoma
12.3.9. Other
12.4. Europe
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By End Users
12.4.1. Hospitals
and Clinics
12.4.2. Diagnostic
centers
12.4.3. Others
12.5. Europe
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
12.5.1.1.1. Diagnosis
12.5.1.1.1.1. Positron
Emission Tomography (PET)
12.5.1.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
12.5.1.1.2. Treatment
12.5.1.1.2.1. Radioactive
iodine therapy
12.5.1.1.2.2. Brachytherapy
12.5.1.1.2.3. Chemotherapy
12.5.1.1.2.4. Hormone
Therapy
12.5.1.1.2.5. Proton
Therapy
12.5.1.1.2.6. Alpha
emitters
12.5.1.1.2.7. Stereotactic
body radiotherapy
12.5.1.1.2.8. Others
12.5.1.2. France Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.1.2.1. Thyroid disease
12.5.1.2.2. Gall bladder disease
12.5.1.2.3. Heart conditions
12.5.1.2.4. Cancer
12.5.1.2.5. Alzheimer’s disease
12.5.1.2.6. Endocrine Tumors
12.5.1.2.7. Neurology Disorders
12.5.1.2.8. Lymphoma
12.5.1.2.9. Other
12.5.1.3. France Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
12.5.1.3.1. Hospitals and Clinics
12.5.1.3.2. Diagnostic centers
12.5.1.3.3. Others
12.5.2. The UK
12.5.2.1. The UK Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
12.5.2.1.1. Diagnosis
12.5.2.1.1.1. Positron
Emission Tomography (PET)
12.5.2.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
12.5.2.1.2. Treatment
12.5.2.1.2.1. Radioactive
iodine therapy
12.5.2.1.2.2. Brachytherapy
12.5.2.1.2.3. Chemotherapy
12.5.2.1.2.4. Hormone
Therapy
12.5.2.1.2.5. Proton
Therapy
12.5.2.1.2.6. Alpha
emitters
12.5.2.1.2.7. Stereotactic
body radiotherapy
12.5.2.1.2.8. Others
12.5.2.2. The UK Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.2.2.1. Thyroid disease
12.5.2.2.2. Gall bladder disease
12.5.2.2.3. Heart conditions
12.5.2.2.4. Cancer
12.5.2.2.5. Alzheimer’s disease
12.5.2.2.6. Endocrine Tumors
12.5.2.2.7. Neurology Disorders
12.5.2.2.8. Lymphoma
12.5.2.2.9. Other
12.5.2.3. The UK Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
12.5.2.3.1. Hospitals and Clinics
12.5.2.3.2. Diagnostic centers
12.5.2.3.3. Others
12.5.3. Spain
12.5.3.1. Spain Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
12.5.3.1.1. Diagnosis
12.5.3.1.1.1. Positron
Emission Tomography (PET)
12.5.3.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
12.5.3.1.2. Treatment
12.5.3.1.2.1. Radioactive
iodine therapy
12.5.3.1.2.2. Brachytherapy
12.5.3.1.2.3. Chemotherapy
12.5.3.1.2.4. Hormone
Therapy
12.5.3.1.2.5. Proton
Therapy
12.5.3.1.2.6. Alpha
emitters
12.5.3.1.2.7. Stereotactic
body radiotherapy
12.5.3.1.2.8. Others
12.5.3.2. Spain Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.3.2.1. Thyroid disease
12.5.3.2.2. Gall bladder disease
12.5.3.2.3. Heart conditions
12.5.3.2.4. Cancer
12.5.3.2.5. Alzheimer’s disease
12.5.3.2.6. Endocrine Tumors
12.5.3.2.7. Neurology Disorders
12.5.3.2.8. Lymphoma
12.5.3.2.9. Other
12.5.3.3. Spain Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
12.5.3.3.1. Hospitals and Clinics
12.5.3.3.2. Diagnostic centers
12.5.3.3.3. Others
12.5.4. Germany
12.5.4.1. Germany Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.4.1.1. Diagnosis
12.5.4.1.1.1. Positron
Emission Tomography (PET)
12.5.4.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
12.5.4.1.2. Treatment
12.5.4.1.2.1. Radioactive
iodine therapy
12.5.4.1.2.2. Brachytherapy
12.5.4.1.2.3. Chemotherapy
12.5.4.1.2.4. Hormone
Therapy
12.5.4.1.2.5. Proton
Therapy
12.5.4.1.2.6. Alpha
emitters
12.5.4.1.2.7. Stereotactic
body radiotherapy
12.5.4.1.2.8. Others
12.5.4.2. Germany Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.4.2.1. Thyroid disease
12.5.4.2.2. Gall bladder disease
12.5.4.2.3. Heart conditions
12.5.4.2.4. Cancer
12.5.4.2.5. Alzheimer’s disease
12.5.4.2.6. Endocrine Tumors
12.5.4.2.7. Neurology Disorders
12.5.4.2.8. Lymphoma
12.5.4.2.9. Other
12.5.4.3. Germany Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.4.3.1. Hospitals and Clinics
12.5.4.3.2. Diagnostic centers
12.5.4.3.3. Others
12.5.5. Italy
12.5.5.1. Italy Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
12.5.5.1.1. Diagnosis
12.5.5.1.1.1. Positron
Emission Tomography (PET)
12.5.5.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
12.5.5.1.2. Treatment
12.5.5.1.2.1. Radioactive
iodine therapy
12.5.5.1.2.2. Brachytherapy
12.5.5.1.2.3. Chemotherapy
12.5.5.1.2.4. Hormone
Therapy
12.5.5.1.2.5. Proton
Therapy
12.5.5.1.2.6. Alpha
emitters
12.5.5.1.2.7. Stereotactic
body radiotherapy
12.5.5.1.2.8. Others
12.5.5.2. Italy Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.5.2.1. Thyroid disease
12.5.5.2.2. Gall bladder disease
12.5.5.2.3. Heart conditions
12.5.5.2.4. Cancer
12.5.5.2.5. Alzheimer’s disease
12.5.5.2.6. Endocrine Tumors
12.5.5.2.7. Neurology Disorders
12.5.5.2.8. Lymphoma
12.5.5.2.9. Other
12.5.5.3. Italy Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
12.5.5.3.1. Hospitals and Clinics
12.5.5.3.2. Diagnostic centers
12.5.5.3.3. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.6.1.1. Diagnosis
12.5.6.1.1.1. Positron
Emission Tomography (PET)
12.5.6.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
12.5.6.1.2. Treatment
12.5.6.1.2.1. Radioactive
iodine therapy
12.5.6.1.2.2. Brachytherapy
12.5.6.1.2.3. Chemotherapy
12.5.6.1.2.4. Hormone
Therapy
12.5.6.1.2.5. Proton
Therapy
12.5.6.1.2.6. Alpha
emitters
12.5.6.1.2.7. Stereotactic
body radiotherapy
12.5.6.1.2.8. Others
12.5.6.2. Nordic Countries Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.6.2.1. Thyroid disease
12.5.6.2.2. Gall bladder disease
12.5.6.2.3. Heart conditions
12.5.6.2.4. Cancer
12.5.6.2.5. Alzheimer’s disease
12.5.6.2.6. Endocrine Tumors
12.5.6.2.7. Neurology Disorders
12.5.6.2.8. Lymphoma
12.5.6.2.9. Other
12.5.6.3. Nordic Countries Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.6.3.1. Hospitals and Clinics
12.5.6.3.2. Diagnostic centers
12.5.6.3.3. Others
12.5.6.4. Nordic Countries Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.7.1.1. Diagnosis
12.5.7.1.1.1. Positron
Emission Tomography (PET)
12.5.7.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
12.5.7.1.2. Treatment
12.5.7.1.2.1. Radioactive
iodine therapy
12.5.7.1.2.2. Brachytherapy
12.5.7.1.2.3. Chemotherapy
12.5.7.1.2.4. Hormone
Therapy
12.5.7.1.2.5. Proton
Therapy
12.5.7.1.2.6. Alpha
emitters
12.5.7.1.2.7. Stereotactic
body radiotherapy
12.5.7.1.2.8. Others
12.5.7.2. Benelux Union Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.7.2.1. Thyroid disease
12.5.7.2.2. Gall bladder disease
12.5.7.2.3. Heart conditions
12.5.7.2.4. Cancer
12.5.7.2.5. Alzheimer’s disease
12.5.7.2.6. Endocrine Tumors
12.5.7.2.7. Neurology Disorders
12.5.7.2.8. Lymphoma
12.5.7.2.9. Other
12.5.7.3. Benelux Union Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.7.3.1. Hospitals and Clinics
12.5.7.3.2. Diagnostic centers
12.5.7.3.3. Others
12.5.7.4. Benelux Union Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.8.1.1. Diagnosis
12.5.8.1.1.1. Positron
Emission Tomography (PET)
12.5.8.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
12.5.8.1.2. Treatment
12.5.8.1.2.1. Radioactive
iodine therapy
12.5.8.1.2.2. Brachytherapy
12.5.8.1.2.3. Chemotherapy
12.5.8.1.2.4. Hormone
Therapy
12.5.8.1.2.5. Proton
Therapy
12.5.8.1.2.6. Alpha
emitters
12.5.8.1.2.7. Stereotactic
body radiotherapy
12.5.8.1.2.8. Others
12.5.8.2. Rest of Europe Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.8.2.1. Thyroid disease
12.5.8.2.2. Gall bladder disease
12.5.8.2.3. Heart conditions
12.5.8.2.4. Cancer
12.5.8.2.5. Alzheimer’s disease
12.5.8.2.6. Endocrine Tumors
12.5.8.2.7. Neurology Disorders
12.5.8.2.8. Lymphoma
12.5.8.2.9. Other
12.5.8.3. Rest of Europe Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.8.3.1. Hospitals and Clinics
12.5.8.3.2. Diagnostic centers
12.5.8.3.3. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By Type
12.6.3. By
Application
12.6.4. By End
Users
13. Asia Pacific Nuclear Medicine Market Analysis and Forecasts,
2022 - 2030
13.1. Overview
13.1.1. Asia
Pacific Nuclear Medicine Market Revenue (US$ Mn)
13.2. Asia
Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Diagnosis
13.2.1.1. Positron Emission Tomography (PET)
13.2.1.2. Single-Photon Emission Computed Tomography (SPECT).
13.2.2. Treatment
13.2.2.1. Radioactive iodine therapy
13.2.2.2. Brachytherapy
13.2.2.3. Chemotherapy
13.2.2.4. Hormone Therapy
13.2.2.5. Proton Therapy
13.2.2.6. Alpha emitters
13.2.2.7. Stereotactic body radiotherapy
13.2.2.8. Others
13.3. Asia
Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Thyroid
disease
13.3.2. Gall
bladder disease
13.3.3. Heart
conditions
13.3.4. Cancer
13.3.5. Alzheimer’s
disease
13.3.6. Endocrine
Tumors
13.3.7. Neurology
Disorders
13.3.8. Lymphoma
13.3.9. Other
13.4. Asia
Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By End Users
13.4.1. Hospitals
and Clinics
13.4.2. Diagnostic
centers
13.4.3. Others
13.5. Asia
Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
13.5.1.1.1. Diagnosis
13.5.1.1.1.1. Positron
Emission Tomography (PET)
13.5.1.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
13.5.1.1.2. Treatment
13.5.1.1.2.1. Radioactive
iodine therapy
13.5.1.1.2.2. Brachytherapy
13.5.1.1.2.3. Chemotherapy
13.5.1.1.2.4. Hormone
Therapy
13.5.1.1.2.5. Proton
Therapy
13.5.1.1.2.6. Alpha
emitters
13.5.1.1.2.7. Stereotactic
body radiotherapy
13.5.1.1.2.8. Others
13.5.1.2. China Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.1.2.1. Thyroid disease
13.5.1.2.2. Gall bladder disease
13.5.1.2.3. Heart conditions
13.5.1.2.4. Cancer
13.5.1.2.5. Alzheimer’s disease
13.5.1.2.6. Endocrine Tumors
13.5.1.2.7. Neurology Disorders
13.5.1.2.8. Lymphoma
13.5.1.2.9. Other
13.5.1.3. China Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
13.5.1.3.1. Hospitals and Clinics
13.5.1.3.2. Diagnostic centers
13.5.1.3.3. Others
13.5.2. Japan
13.5.2.1. Japan Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
13.5.2.1.1. Diagnosis
13.5.2.1.1.1. Positron
Emission Tomography (PET)
13.5.2.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
13.5.2.1.2. Treatment
13.5.2.1.2.1. Radioactive
iodine therapy
13.5.2.1.2.2. Brachytherapy
13.5.2.1.2.3. Chemotherapy
13.5.2.1.2.4. Hormone
Therapy
13.5.2.1.2.5. Proton
Therapy
13.5.2.1.2.6. Alpha
emitters
13.5.2.1.2.7. Stereotactic
body radiotherapy
13.5.2.1.2.8. Others
13.5.2.2. Japan Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.2.2.1. Thyroid disease
13.5.2.2.2. Gall bladder disease
13.5.2.2.3. Heart conditions
13.5.2.2.4. Cancer
13.5.2.2.5. Alzheimer’s disease
13.5.2.2.6. Endocrine Tumors
13.5.2.2.7. Neurology Disorders
13.5.2.2.8. Lymphoma
13.5.2.2.9. Other
13.5.2.3. Japan Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
13.5.2.3.1. Hospitals and Clinics
13.5.2.3.2. Diagnostic centers
13.5.2.3.3. Others
13.5.3. India
13.5.3.1. India Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
13.5.3.1.1. Diagnosis
13.5.3.1.1.1. Positron
Emission Tomography (PET)
13.5.3.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
13.5.3.1.2. Treatment
13.5.3.1.2.1. Radioactive
iodine therapy
13.5.3.1.2.2. Brachytherapy
13.5.3.1.2.3. Chemotherapy
13.5.3.1.2.4. Hormone
Therapy
13.5.3.1.2.5. Proton
Therapy
13.5.3.1.2.6. Alpha
emitters
13.5.3.1.2.7. Stereotactic
body radiotherapy
13.5.3.1.2.8. Others
13.5.3.2. India Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.3.2.1. Thyroid disease
13.5.3.2.2. Gall bladder disease
13.5.3.2.3. Heart conditions
13.5.3.2.4. Cancer
13.5.3.2.5. Alzheimer’s disease
13.5.3.2.6. Endocrine Tumors
13.5.3.2.7. Neurology Disorders
13.5.3.2.8. Lymphoma
13.5.3.2.9. Other
13.5.3.3. India Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
13.5.3.3.1. Hospitals and Clinics
13.5.3.3.2. Diagnostic centers
13.5.3.3.3. Others
13.5.4. New
Zealand
13.5.4.1. New Zealand Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.4.1.1. Diagnosis
13.5.4.1.1.1. Positron
Emission Tomography (PET)
13.5.4.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
13.5.4.1.2. Treatment
13.5.4.1.2.1. Radioactive
iodine therapy
13.5.4.1.2.2. Brachytherapy
13.5.4.1.2.3. Chemotherapy
13.5.4.1.2.4. Hormone
Therapy
13.5.4.1.2.5. Proton
Therapy
13.5.4.1.2.6. Alpha
emitters
13.5.4.1.2.7. Stereotactic
body radiotherapy
13.5.4.1.2.8. Others
13.5.4.2. New Zealand Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.4.2.1. Thyroid disease
13.5.4.2.2. Gall bladder disease
13.5.4.2.3. Heart conditions
13.5.4.2.4. Cancer
13.5.4.2.5. Alzheimer’s disease
13.5.4.2.6. Endocrine Tumors
13.5.4.2.7. Neurology Disorders
13.5.4.2.8. Lymphoma
13.5.4.2.9. Other
13.5.4.3. New Zealand Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.4.3.1. Hospitals and Clinics
13.5.4.3.2. Diagnostic centers
13.5.4.3.3. Others
13.5.5. Australia
13.5.5.1. Australia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.5.1.1. Diagnosis
13.5.5.1.1.1. Positron
Emission Tomography (PET)
13.5.5.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
13.5.5.1.2. Treatment
13.5.5.1.2.1. Radioactive
iodine therapy
13.5.5.1.2.2. Brachytherapy
13.5.5.1.2.3. Chemotherapy
13.5.5.1.2.4. Hormone
Therapy
13.5.5.1.2.5. Proton
Therapy
13.5.5.1.2.6. Alpha
emitters
13.5.5.1.2.7. Stereotactic
body radiotherapy
13.5.5.1.2.8. Others
13.5.5.2. Australia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.5.2.1. Thyroid disease
13.5.5.2.2. Gall bladder disease
13.5.5.2.3. Heart conditions
13.5.5.2.4. Cancer
13.5.5.2.5. Alzheimer’s disease
13.5.5.2.6. Endocrine Tumors
13.5.5.2.7. Neurology Disorders
13.5.5.2.8. Lymphoma
13.5.5.2.9. Other
13.5.5.3. Australia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.5.3.1. Hospitals and Clinics
13.5.5.3.2. Diagnostic centers
13.5.5.3.3. Others
13.5.6. South
Korea
13.5.6.1. South Korea Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.6.1.1. Diagnosis
13.5.6.1.1.1. Positron
Emission Tomography (PET)
13.5.6.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
13.5.6.1.2. Treatment
13.5.6.1.2.1. Radioactive
iodine therapy
13.5.6.1.2.2. Brachytherapy
13.5.6.1.2.3. Chemotherapy
13.5.6.1.2.4. Hormone
Therapy
13.5.6.1.2.5. Proton
Therapy
13.5.6.1.2.6. Alpha
emitters
13.5.6.1.2.7. Stereotactic
body radiotherapy
13.5.6.1.2.8. Others
13.5.6.2. South Korea Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.6.2.1. Thyroid disease
13.5.6.2.2. Gall bladder disease
13.5.6.2.3. Heart conditions
13.5.6.2.4. Cancer
13.5.6.2.5. Alzheimer’s disease
13.5.6.2.6. Endocrine Tumors
13.5.6.2.7. Neurology Disorders
13.5.6.2.8. Lymphoma
13.5.6.2.9. Other
13.5.6.3. South Korea Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.6.3.1. Hospitals and Clinics
13.5.6.3.2. Diagnostic centers
13.5.6.3.3. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.7.1.1. Diagnosis
13.5.7.1.1.1. Positron
Emission Tomography (PET)
13.5.7.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
13.5.7.1.2. Treatment
13.5.7.1.2.1. Radioactive
iodine therapy
13.5.7.1.2.2. Brachytherapy
13.5.7.1.2.3. Chemotherapy
13.5.7.1.2.4. Hormone
Therapy
13.5.7.1.2.5. Proton
Therapy
13.5.7.1.2.6. Alpha
emitters
13.5.7.1.2.7. Stereotactic
body radiotherapy
13.5.7.1.2.8. Others
13.5.7.2. Southeast Asia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.7.2.1. Thyroid disease
13.5.7.2.2. Gall bladder disease
13.5.7.2.3. Heart conditions
13.5.7.2.4. Cancer
13.5.7.2.5. Alzheimer’s disease
13.5.7.2.6. Endocrine Tumors
13.5.7.2.7. Neurology Disorders
13.5.7.2.8. Lymphoma
13.5.7.2.9. Other
13.5.7.3. Southeast Asia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.7.3.1. Hospitals and Clinics
13.5.7.3.2. Diagnostic centers
13.5.7.3.3. Others
13.5.7.4. Southeast Asia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Type
13.5.8.1.1. Diagnosis
13.5.8.1.1.1. Positron
Emission Tomography (PET)
13.5.8.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
13.5.8.1.2. Treatment
13.5.8.1.2.1. Radioactive
iodine therapy
13.5.8.1.2.2. Brachytherapy
13.5.8.1.2.3. Chemotherapy
13.5.8.1.2.4. Hormone
Therapy
13.5.8.1.2.5. Proton
Therapy
13.5.8.1.2.6. Alpha
emitters
13.5.8.1.2.7. Stereotactic
body radiotherapy
13.5.8.1.2.8. Others
13.5.8.2. Rest of Asia Pacific Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Application
13.5.8.2.1. Thyroid disease
13.5.8.2.2. Gall bladder disease
13.5.8.2.3. Heart conditions
13.5.8.2.4. Cancer
13.5.8.2.5. Alzheimer’s disease
13.5.8.2.6. Endocrine Tumors
13.5.8.2.7. Neurology Disorders
13.5.8.2.8. Lymphoma
13.5.8.2.9. Other
13.5.8.3. Rest of Asia Pacific Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By End Users
13.5.8.3.1. Hospitals and Clinics
13.5.8.3.2. Diagnostic centers
13.5.8.3.3. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By Type
13.6.3. By
Application
13.6.4. By End
Users
14. Middle East and Africa Nuclear Medicine Market Analysis and
Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle
East and Africa Nuclear Medicine Market Revenue (US$ Mn)
14.2. Middle
East and Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Diagnosis
14.2.1.1. Positron Emission Tomography (PET)
14.2.1.2. Single-Photon Emission Computed Tomography (SPECT).
14.2.2. Treatment
14.2.2.1. Radioactive iodine therapy
14.2.2.2. Brachytherapy
14.2.2.3. Chemotherapy
14.2.2.4. Hormone Therapy
14.2.2.5. Proton Therapy
14.2.2.6. Alpha emitters
14.2.2.7. Stereotactic body radiotherapy
14.2.2.8. Others
14.3. Middle
East and Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By
Application
14.3.1. Thyroid
disease
14.3.2. Gall
bladder disease
14.3.3. Heart
conditions
14.3.4. Cancer
14.3.5. Alzheimer’s
disease
14.3.6. Endocrine
Tumors
14.3.7. Neurology
Disorders
14.3.8. Lymphoma
14.3.9. Other
14.4. Middle
East and Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By End
Users
14.4.1. Hospitals
and Clinics
14.4.2. Diagnostic
centers
14.4.3. Others
14.5. Middle
East and Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.1.1.1. Diagnosis
14.5.1.1.1.1. Positron
Emission Tomography (PET)
14.5.1.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
14.5.1.1.2. Treatment
14.5.1.1.2.1. Radioactive
iodine therapy
14.5.1.1.2.2. Brachytherapy
14.5.1.1.2.3. Chemotherapy
14.5.1.1.2.4. Hormone
Therapy
14.5.1.1.2.5. Proton
Therapy
14.5.1.1.2.6. Alpha
emitters
14.5.1.1.2.7. Stereotactic
body radiotherapy
14.5.1.1.2.8. Others
14.5.1.2. Saudi Arabia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.1.2.1. Thyroid disease
14.5.1.2.2. Gall bladder disease
14.5.1.2.3. Heart conditions
14.5.1.2.4. Cancer
14.5.1.2.5. Alzheimer’s disease
14.5.1.2.6. Endocrine Tumors
14.5.1.2.7. Neurology Disorders
14.5.1.2.8. Lymphoma
14.5.1.2.9. Other
14.5.1.3. Saudi Arabia Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
14.5.1.3.1. Hospitals and Clinics
14.5.1.3.2. Diagnostic centers
14.5.1.3.3. Others
14.5.2. UAE
14.5.2.1. UAE Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.2.1.1. Diagnosis
14.5.2.1.1.1. Positron
Emission Tomography (PET)
14.5.2.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
14.5.2.1.2. Treatment
14.5.2.1.2.1. Radioactive
iodine therapy
14.5.2.1.2.2. Brachytherapy
14.5.2.1.2.3. Chemotherapy
14.5.2.1.2.4. Hormone
Therapy
14.5.2.1.2.5. Proton
Therapy
14.5.2.1.2.6. Alpha
emitters
14.5.2.1.2.7. Stereotactic
body radiotherapy
14.5.2.1.2.8. Others
14.5.2.2. UAE Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.2.2.1. Thyroid disease
14.5.2.2.2. Gall bladder disease
14.5.2.2.3. Heart conditions
14.5.2.2.4. Cancer
14.5.2.2.5. Alzheimer’s disease
14.5.2.2.6. Endocrine Tumors
14.5.2.2.7. Neurology Disorders
14.5.2.2.8. Lymphoma
14.5.2.2.9. Other
14.5.2.3. UAE Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By
End Users
14.5.2.3.1. Hospitals and Clinics
14.5.2.3.2. Diagnostic centers
14.5.2.3.3. Others
14.5.3. Egypt
14.5.3.1. Egypt Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
14.5.3.1.1. Diagnosis
14.5.3.1.1.1. Positron
Emission Tomography (PET)
14.5.3.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
14.5.3.1.2. Treatment
14.5.3.1.2.1. Radioactive
iodine therapy
14.5.3.1.2.2. Brachytherapy
14.5.3.1.2.3. Chemotherapy
14.5.3.1.2.4. Hormone
Therapy
14.5.3.1.2.5. Proton
Therapy
14.5.3.1.2.6. Alpha
emitters
14.5.3.1.2.7. Stereotactic
body radiotherapy
14.5.3.1.2.8. Others
14.5.3.2. Egypt Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.3.2.1. Thyroid disease
14.5.3.2.2. Gall bladder disease
14.5.3.2.3. Heart conditions
14.5.3.2.4. Cancer
14.5.3.2.5. Alzheimer’s disease
14.5.3.2.6. Endocrine Tumors
14.5.3.2.7. Neurology Disorders
14.5.3.2.8. Lymphoma
14.5.3.2.9. Other
14.5.3.3. Egypt Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
14.5.3.3.1. Hospitals and Clinics
14.5.3.3.2. Diagnostic centers
14.5.3.3.3. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
14.5.4.1.1. Diagnosis
14.5.4.1.1.1. Positron
Emission Tomography (PET)
14.5.4.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
14.5.4.1.2. Treatment
14.5.4.1.2.1. Radioactive
iodine therapy
14.5.4.1.2.2. Brachytherapy
14.5.4.1.2.3. Chemotherapy
14.5.4.1.2.4. Hormone
Therapy
14.5.4.1.2.5. Proton
Therapy
14.5.4.1.2.6. Alpha
emitters
14.5.4.1.2.7. Stereotactic
body radiotherapy
14.5.4.1.2.8. Others
14.5.4.2. Kuwait Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.4.2.1. Thyroid disease
14.5.4.2.2. Gall bladder disease
14.5.4.2.3. Heart conditions
14.5.4.2.4. Cancer
14.5.4.2.5. Alzheimer’s disease
14.5.4.2.6. Endocrine Tumors
14.5.4.2.7. Neurology Disorders
14.5.4.2.8. Lymphoma
14.5.4.2.9. Other
14.5.4.3. Kuwait Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
14.5.4.3.1. Hospitals and Clinics
14.5.4.3.2. Diagnostic centers
14.5.4.3.3. Others
14.5.5. South
Africa
14.5.5.1. South Africa Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.5.1.1. Diagnosis
14.5.5.1.1.1. Positron
Emission Tomography (PET)
14.5.5.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
14.5.5.1.2. Treatment
14.5.5.1.2.1. Radioactive
iodine therapy
14.5.5.1.2.2. Brachytherapy
14.5.5.1.2.3. Chemotherapy
14.5.5.1.2.4. Hormone
Therapy
14.5.5.1.2.5. Proton
Therapy
14.5.5.1.2.6. Alpha
emitters
14.5.5.1.2.7. Stereotactic
body radiotherapy
14.5.5.1.2.8. Others
14.5.5.2. South Africa Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.5.2.1. Thyroid disease
14.5.5.2.2. Gall bladder disease
14.5.5.2.3. Heart conditions
14.5.5.2.4. Cancer
14.5.5.2.5. Alzheimer’s disease
14.5.5.2.6. Endocrine Tumors
14.5.5.2.7. Neurology Disorders
14.5.5.2.8. Lymphoma
14.5.5.2.9. Other
14.5.5.3. South Africa Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
14.5.5.3.1. Hospitals and Clinics
14.5.5.3.2. Diagnostic centers
14.5.5.3.3. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Nuclear Medicine Market
Revenue (US$ Mn) and Forecasts, By Type
14.5.6.1.1. Diagnosis
14.5.6.1.1.1. Positron
Emission Tomography (PET)
14.5.6.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
14.5.6.1.2. Treatment
14.5.6.1.2.1. Radioactive
iodine therapy
14.5.6.1.2.2. Brachytherapy
14.5.6.1.2.3. Chemotherapy
14.5.6.1.2.4. Hormone
Therapy
14.5.6.1.2.5. Proton
Therapy
14.5.6.1.2.6. Alpha
emitters
14.5.6.1.2.7. Stereotactic
body radiotherapy
14.5.6.1.2.8. Others
14.5.6.2. Rest of Middle East & Africa Nuclear Medicine Market
Revenue (US$ Mn) and Forecasts, By Application
14.5.6.2.1. Thyroid disease
14.5.6.2.2. Gall bladder disease
14.5.6.2.3. Heart conditions
14.5.6.2.4. Cancer
14.5.6.2.5. Alzheimer’s disease
14.5.6.2.6. Endocrine Tumors
14.5.6.2.7. Neurology Disorders
14.5.6.2.8. Lymphoma
14.5.6.2.9. Other
14.5.6.3. Rest of Middle East & Africa Nuclear Medicine Market
Revenue (US$ Mn) and Forecasts, By End Users
14.5.6.3.1. Hospitals and Clinics
14.5.6.3.2. Diagnostic centers
14.5.6.3.3. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By Type
14.6.3. By
Application
14.6.4. By End
Users
15. Latin America Nuclear Medicine Market Analysis and Forecasts,
2022 - 2030
15.1. Overview
15.1.1. Latin
America Nuclear Medicine Market Revenue (US$ Mn)
15.2. Latin
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Diagnosis
15.2.1.1. Positron Emission Tomography (PET)
15.2.1.2. Single-Photon Emission Computed Tomography (SPECT).
15.2.2. Treatment
15.2.2.1. Radioactive iodine therapy
15.2.2.2. Brachytherapy
15.2.2.3. Chemotherapy
15.2.2.4. Hormone Therapy
15.2.2.5. Proton Therapy
15.2.2.6. Alpha emitters
15.2.2.7. Stereotactic body radiotherapy
15.2.2.8. Others
15.3. Latin
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1. Thyroid
disease
15.3.2. Gall
bladder disease
15.3.3. Heart
conditions
15.3.4. Cancer
15.3.5. Alzheimer’s
disease
15.3.6. Endocrine
Tumors
15.3.7. Neurology
Disorders
15.3.8. Lymphoma
15.3.9. Other
15.4. Latin
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By End Users
15.4.1. Hospitals
and Clinics
15.4.2. Diagnostic
centers
15.4.3. Others
15.5. Latin
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Type
15.5.1.1.1. Diagnosis
15.5.1.1.1.1. Positron
Emission Tomography (PET)
15.5.1.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
15.5.1.1.2. Treatment
15.5.1.1.2.1. Radioactive
iodine therapy
15.5.1.1.2.2. Brachytherapy
15.5.1.1.2.3. Chemotherapy
15.5.1.1.2.4. Hormone
Therapy
15.5.1.1.2.5. Proton
Therapy
15.5.1.1.2.6. Alpha
emitters
15.5.1.1.2.7. Stereotactic
body radiotherapy
15.5.1.1.2.8. Others
15.5.1.2. Brazil Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By Application
15.5.1.2.1. Thyroid disease
15.5.1.2.2. Gall bladder disease
15.5.1.2.3. Heart conditions
15.5.1.2.4. Cancer
15.5.1.2.5. Alzheimer’s disease
15.5.1.2.6. Endocrine Tumors
15.5.1.2.7. Neurology Disorders
15.5.1.2.8. Lymphoma
15.5.1.2.9. Other
15.5.1.3. Brazil Nuclear Medicine Market Revenue (US$ Mn) and Forecasts,
By End Users
15.5.1.3.1. Hospitals and Clinics
15.5.1.3.2. Diagnostic centers
15.5.1.3.3. Others
15.5.2. Argentina
15.5.2.1. Argentina Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Type
15.5.2.1.1. Diagnosis
15.5.2.1.1.1. Positron
Emission Tomography (PET)
15.5.2.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
15.5.2.1.2. Treatment
15.5.2.1.2.1. Radioactive
iodine therapy
15.5.2.1.2.2. Brachytherapy
15.5.2.1.2.3. Chemotherapy
15.5.2.1.2.4. Hormone
Therapy
15.5.2.1.2.5. Proton
Therapy
15.5.2.1.2.6. Alpha
emitters
15.5.2.1.2.7. Stereotactic
body radiotherapy
15.5.2.1.2.8. Others
15.5.2.2. Argentina Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.2.2.1. Thyroid disease
15.5.2.2.2. Gall bladder disease
15.5.2.2.3. Heart conditions
15.5.2.2.4. Cancer
15.5.2.2.5. Alzheimer’s disease
15.5.2.2.6. Endocrine Tumors
15.5.2.2.7. Neurology Disorders
15.5.2.2.8. Lymphoma
15.5.2.2.9. Other
15.5.2.3. Argentina Nuclear Medicine Market Revenue (US$ Mn) and
Forecasts, By End Users
15.5.2.3.1. Hospitals and Clinics
15.5.2.3.2. Diagnostic centers
15.5.2.3.3. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Type
15.5.3.1.1. Diagnosis
15.5.3.1.1.1. Positron
Emission Tomography (PET)
15.5.3.1.1.2. Single-Photon
Emission Computed Tomography (SPECT).
15.5.3.1.2. Treatment
15.5.3.1.2.1. Radioactive
iodine therapy
15.5.3.1.2.2. Brachytherapy
15.5.3.1.2.3. Chemotherapy
15.5.3.1.2.4. Hormone
Therapy
15.5.3.1.2.5. Proton
Therapy
15.5.3.1.2.6. Alpha
emitters
15.5.3.1.2.7. Stereotactic
body radiotherapy
15.5.3.1.2.8. Others
15.5.3.2. Rest of Latin America Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Application
15.5.3.2.1. Thyroid disease
15.5.3.2.2. Gall bladder disease
15.5.3.2.3. Heart conditions
15.5.3.2.4. Cancer
15.5.3.2.5. Alzheimer’s disease
15.5.3.2.6. Endocrine Tumors
15.5.3.2.7. Neurology Disorders
15.5.3.2.8. Lymphoma
15.5.3.2.9. Other
15.5.3.3. Rest of Latin America Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By End Users
15.5.3.3.1. Hospitals and Clinics
15.5.3.3.2. Diagnostic centers
15.5.3.3.3. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By Type
15.6.3. By
Application
15.6.4. By End
Users
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2021
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Advanced
Accelerator Applications
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Alliance
Medical GmbH
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. B. J.
Madan & Co.
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Bracco
Diagnostic Inc.
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. BWX
Technologies. Inc.
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Cardinal
Health.
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT Analysis
17.6.7. Business
Strategies
17.7. Curium
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. EDH
Nuclear Medicine & Healthcare Services Ltd. Co.
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. General
Electric Company
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. IBA
Radiopharma Solutions
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Jubilant
Pharma Limited
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Lantheus
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business Strategies
17.13. Other
Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.